within Pharmacolibrary.Drugs.ATC.N;

model N03AG05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 4.1666666666666665e-05,
    adminDuration  = 600,
    adminMass      = 1200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N03AG05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Progabide is a gamma-aminobutyric acid (GABA) agonist anticonvulsant drug previously used in the treatment of epilepsy. It acts as a GABA receptor agonist to enhance inhibitory neurotransmission. Its use is discontinued or very limited today, and it is not approved in most countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical adult population; no detailed human PK studies published in English literature, values are based on secondary pharmacology sources and estimation.</p><h4>References</h4><ol><li><p>Farraj, NF, et al., &amp; Stevens, HN (1988). The stability and solubility of progabide and its related metabolic derivatives. <i>Pharmaceutical research</i> 5(4) 226–231. DOI:<a href=&quot;https://doi.org/10.1023/a:1015941729400&quot;>10.1023/a:1015941729400</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3247302/&quot;>https://pubmed.ncbi.nlm.nih.gov/3247302</a></p></li><li><p>Spina, E, et al., &amp; Perucca, E (1996). Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. <i>Clinical pharmacokinetics</i> 31(3) 198–214. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199631030-00004&quot;>10.2165/00003088-199631030-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8877250/&quot;>https://pubmed.ncbi.nlm.nih.gov/8877250</a></p></li><li><p>Brunet, C, et al., &amp; Lhermitte, M (1989). Acid metabolite of progabide pharmacokinetics following single administration in the rabbit with special references to HPLC and (3H) muscimol radioreceptor assay. <i>European journal of drug metabolism and pharmacokinetics</i> 14(4) 257–262. DOI:<a href=&quot;https://doi.org/10.1007/BF03190108&quot;>10.1007/BF03190108</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2633919/&quot;>https://pubmed.ncbi.nlm.nih.gov/2633919</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N03AG05;
